AAAAAA

   
Results: 1-7 |
Results: 7
IN-VITRO P24 ANTIGEN-STIMULATED LYMPHOCYTE-PROLIFERATION AND BETA-CHEMOKINE PRODUCTION IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1)-SEROPOSITIVE SUBJECTS AFTER IMMUNIZATION WITH AN INACTIVATED GP120-DEPLETEDHIV-1 IMMUNOGEN (REMUNE)
Authors: MOSS RB WALLACE MR LANZA P GIERMAKOWSKA W JENSEN FC THEOFAN G CHAMBERLIN C RICHIERI SP CARLO DJ
Citation: Rb. Moss et al., IN-VITRO P24 ANTIGEN-STIMULATED LYMPHOCYTE-PROLIFERATION AND BETA-CHEMOKINE PRODUCTION IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1)-SEROPOSITIVE SUBJECTS AFTER IMMUNIZATION WITH AN INACTIVATED GP120-DEPLETEDHIV-1 IMMUNOGEN (REMUNE), Clinical and diagnostic laboratory immunology, 5(3), 1998, pp. 308-312
WHOLE-KILLED GP120-DEPLETED HIV-1 ANTIGEN IN A MURINE MODEL FOR PROPHYLACTIC VACCINATION
Authors: LANZA P MOSS RB GIERMAKOWSKA W HANCOCK RB RICHIERI SP THEOFA G JENSEN FC SALK PL CARLO DJ
Citation: P. Lanza et al., WHOLE-KILLED GP120-DEPLETED HIV-1 ANTIGEN IN A MURINE MODEL FOR PROPHYLACTIC VACCINATION, Vaccine, 16(7), 1998, pp. 727-731
HIV-1-SPECIFIC FUNCTIONAL IMMUNE MEASUREMENTS AS MARKERS OF DISEASE PROGRESSION
Authors: MOSS RB RICHIERI SP FERRE F DAIGLE AE TRAUGER R THEOFAN G GIERMAKOWSKA W LANZA P BROSTOFF S CARLO DJ JENSEN FC
Citation: Rb. Moss et al., HIV-1-SPECIFIC FUNCTIONAL IMMUNE MEASUREMENTS AS MARKERS OF DISEASE PROGRESSION, Journal of biomedical science, 4(4), 1997, pp. 127-131
CROSS-CLADE IMMUNE-RESPONSES AFTER IMMUNIZATION WITH A WHOLE-KILLED GP120-DEPLETED HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IMMUNOGEN IN INCOMPLETE FREUNDS-ADJUVANT (HIV-1 IMMUNOGEN, REMUNE(TM)) IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 SEROPOSITIVE SUBJECTS
Authors: MOSS RB GIERMAKOWSKA W LANZA P TURNER JL WALLACE MR JENSEN FC THEOFAN G RICHIERI SP CARLO DJ
Citation: Rb. Moss et al., CROSS-CLADE IMMUNE-RESPONSES AFTER IMMUNIZATION WITH A WHOLE-KILLED GP120-DEPLETED HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IMMUNOGEN IN INCOMPLETE FREUNDS-ADJUVANT (HIV-1 IMMUNOGEN, REMUNE(TM)) IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 SEROPOSITIVE SUBJECTS, Viral immunology, 10(4), 1997, pp. 221-228
SAFETY AND IMMUNOGENICITY OF A GP120-DEPLETED, INACTIVATED HIV-1 IMMUNOGEN - RESULTS OF A DOUBLE-BLIND, ADJUVANT CONTROLLED TRIAL
Authors: TRAUGER RJ DAIGLE AE GIERMAKOWSKA W MOSS RB JENSEN F CARLO DJ
Citation: Rj. Trauger et al., SAFETY AND IMMUNOGENICITY OF A GP120-DEPLETED, INACTIVATED HIV-1 IMMUNOGEN - RESULTS OF A DOUBLE-BLIND, ADJUVANT CONTROLLED TRIAL, Journal of acquired immune deficiency syndromes and human retrovirology, 10, 1995, pp. 74-82
AUTOPROLIFERATION IN HIV-1-INFECTED PATIENTS UNDERGOING ACTIVE HIV-1-SPECIFIC IMMUNOTHERAPY
Authors: TRAUGER RJ GIERMAKOWSKA W WORMSLEY S TURNER J JENSEN FC CARLO DJ
Citation: Rj. Trauger et al., AUTOPROLIFERATION IN HIV-1-INFECTED PATIENTS UNDERGOING ACTIVE HIV-1-SPECIFIC IMMUNOTHERAPY, Clinical and experimental immunology, 100(1), 1995, pp. 7-12
SEROLOGICAL AND CELL-MEDIATED IMMUNE-RESPONSE AFTER IMMUNIZATION WITHAN ENVELOPE DEPLETED INACTIVATED HIV-1 IMMUNOGEN - RESULTS OF A 1 YEAR DOUBLE-BLIND ADJUVANT CONTROLLED TRIAL
Authors: TRAUGER RJ GIERMAKOWSKA W COX J LUCAS M JENSEN F CARLO D
Citation: Rj. Trauger et al., SEROLOGICAL AND CELL-MEDIATED IMMUNE-RESPONSE AFTER IMMUNIZATION WITHAN ENVELOPE DEPLETED INACTIVATED HIV-1 IMMUNOGEN - RESULTS OF A 1 YEAR DOUBLE-BLIND ADJUVANT CONTROLLED TRIAL, AIDS research and human retroviruses, 10, 1994, pp. 190000159-190000159
Risultati: 1-7 |